Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.27)
# 3,447
Out of 4,761 analysts
100
Total ratings
35.8%
Success rate
-13.94%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Initiates: Overweight | $84 | $47.37 | +77.33% | 1 | Feb 13, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $105 → $110 | $109.95 | +0.05% | 5 | Feb 12, 2025 | |
| EXEL Exelixis | Maintains: Overweight | $37 → $38 | $36.85 | +3.12% | 4 | Feb 12, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $10 → $7.5 | $5.78 | +29.76% | 9 | Jan 31, 2025 | |
| KROS Keros Therapeutics | Maintains: Overweight | $40 → $15 | $11.02 | +36.12% | 3 | Jan 17, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $52 → $53 | $57.75 | -8.23% | 9 | Jan 10, 2025 | |
| CRDF Cardiff Oncology | Maintains: Overweight | $7 → $10 | $4.75 | +110.53% | 4 | Dec 13, 2024 | |
| RVMD Revolution Medicines | Maintains: Overweight | $57 → $70 | $41.34 | +69.33% | 2 | Nov 7, 2024 | |
| EPIX ESSA Pharma | Downgrades: Neutral | $15 → $2 | $1.72 | +16.28% | 2 | Nov 4, 2024 | |
| BMEA Biomea Fusion | Maintains: Overweight | $10 → $19 | $3.46 | +449.13% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $4.60 | +313.04% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $2.16 | +594.44% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $1.75 | $2.79 | -37.28% | 3 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $3.75 | $0.39 | +865.00% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $4.75 | $3.42 | +38.89% | 4 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $23.49 | +53.26% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $12.43 | +221.80% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $7.00 | +114.29% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $16.87 | +107.47% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2.25 → $3.5 | $0.78 | +348.72% | 3 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $0.81 | +452.83% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $5.54 | +441.52% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.96 | +920.41% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.38 | +44.93% | 3 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $0.97 | +930.93% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $50 | $22.64 | +120.85% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $2.36 | +662.71% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $1.29 | +1,837.98% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $2.64 | -33.71% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $21.62 | -7.49% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $0.87 | +72.39% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $0.45 | +2,120.74% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $5.47 | +539.85% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.57 | +3,721.66% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.99 | +502.01% | 3 | Apr 7, 2020 |
Merus
Feb 13, 2025
Initiates: Overweight
Price Target: $84
Current: $47.37
Upside: +77.33%
Gilead Sciences
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $109.95
Upside: +0.05%
Exelixis
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $36.85
Upside: +3.12%
Iovance Biotherapeutics
Jan 31, 2025
Maintains: Neutral
Price Target: $10 → $7.5
Current: $5.78
Upside: +29.76%
Keros Therapeutics
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $11.02
Upside: +36.12%
Halozyme Therapeutics
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $57.75
Upside: -8.23%
Cardiff Oncology
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $4.75
Upside: +110.53%
Revolution Medicines
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $41.34
Upside: +69.33%
ESSA Pharma
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $1.72
Upside: +16.28%
Biomea Fusion
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $3.46
Upside: +449.13%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $4.60
Upside: +313.04%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.16
Upside: +594.44%
Aug 27, 2024
Downgrades: Neutral
Price Target: $5 → $1.75
Current: $2.79
Upside: -37.28%
Aug 19, 2024
Maintains: Overweight
Price Target: $20 → $3.75
Current: $0.39
Upside: +865.00%
Aug 19, 2024
Maintains: Neutral
Price Target: $6 → $4.75
Current: $3.42
Upside: +38.89%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $23.49
Upside: +53.26%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $12.43
Upside: +221.80%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $7.00
Upside: +114.29%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $16.87
Upside: +107.47%
May 28, 2024
Upgrades: Overweight
Price Target: $2.25 → $3.5
Current: $0.78
Upside: +348.72%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $0.81
Upside: +452.83%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $5.54
Upside: +441.52%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.96
Upside: +920.41%
Apr 5, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.38
Upside: +44.93%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $0.97
Upside: +930.93%
Feb 29, 2024
Maintains: Overweight
Price Target: $60 → $50
Current: $22.64
Upside: +120.85%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $2.36
Upside: +662.71%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $1.29
Upside: +1,837.98%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $2.64
Upside: -33.71%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $21.62
Upside: -7.49%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $0.87
Upside: +72.39%
Mar 10, 2022
Maintains: Overweight
Price Target: $12 → $10
Current: $0.45
Upside: +2,120.74%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $5.47
Upside: +539.85%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.57
Upside: +3,721.66%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.99
Upside: +502.01%